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Abstract: Acute and subacute ischemia of the legs in acute and subacute femoropopliteal 
bypass occlusion is a dramatic situation that endangers the survival of the limbs, depend-
ing on the severity of the ischemia. Different therapy options like percutaneous mechanical 
thrombectomy procedures, which include rotational thrombectomy, have become available in 
recent years, in addition to local lysis and surgical thrombectomy. Surgical thrombectomy using 
the Fogarty catheter technique, in particular, shows an increased incidence of perioperative com-
plications but only small technical success rates in randomized trials. On the other hand, local 
lysis is associated with increased costs due to resource-consuming measures, such as intensive 
monitoring and repeat angiographies, in addition to bleeding complications. In the past, further 
development of the Straub Rotarex® system as an endovascular therapy option has demonstrated 
good success leading to amputation-free survival in multiple studies. At the same time, a low 
rate of complications with use has been documented. Most examinations have been conducted 
in the thigh. To date, there are little investigational data on its use in acutely and subacutely 
occluded femoropopliteal bypasses. In this paper, the current study-based significance of the 
Rotarex system for this indication is analyzed based on the existing literature and the authors’ 
own experiences with 22 patients.
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Introduction
Acute ischemia of the limbs is characterized by a significant reduction in arterial perfu-
sion, which, in addition to the danger of injury to the limbs including amputation, can 
mean life-threatening complications for affected patients. The existing hypoperfusion-
related anaerobic local as well as systemic metabolic situation can have direct negative 
effects on other organ systems such as the kidneys, brain, and heart. The therapeutic 
management to be immediately established therefore includes the decision regarding 
appropriate reperfusion measures in addition to general, mostly intensive care,   measures. 
In the case of acute femoropopliteal bypass occlusions, local lysis has also been estab-
lished as an alternative measure in addition to the established vascular intervention 
(Fogarty maneuvers, endarterectomy – another bypass operation). Therapeutic recom-
mendations based on large randomized studies on local lysis can be found on this in the 
current TASC Working Group Guidelines.1–4 Percutaneous mechanical thrombectomy 
(PMT) has also been proven as an additional therapy option in recent years. Because of 
good study data from the interventional therapy of acute and subacute arterial occlusion, 
more and more attention has been paid to rotational thrombectomy.5 In the meantime, the 
Rotarex® system (Straub Medical, Wangs, Switzerland), with technical enhancements, 
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has become a relevant thrombectomy treatment for arterial 
vessel occlusions. Zeller and Wissgott et al in particular have 
described favorable courses with the Rotarex in systematic 
study analyses following acute recanalization.6–8
The objective of the prospective study was to analyze 
the efficacy of the device in the indication of acute 
femoropopliteal bypass occlusions in 22 patients. The 
patients were followed over a period of 6 months for clinical 
outcome and patency of the femoropopliteal bypass.
PMT with the Rotarex system
The Straub Rotarex thrombectomy system works on the 
Archimedean screw principle, which is generated by a spiral 
rotating at a speed of approximately 40,000 revolutions per 
minute.
The system consists of three individual components that 
can be put together by an experienced team within a few min-
utes. It is operated by a motor unit with an electronic control 
unit, which also displays information on the functionality of the 
rotating helix. Inside the catheter runs a helical conveyor drive, 
which is connected to the motor unit via a magnetic coupling. 
The rapid rotation of the helix generates a permanent vacuum 
inside the catheter, which aspirates the thrombotic material 
in the target lesion and conveys it into a collection bag at the 
end of the catheter. Depending on the size of the system used 
(Rotarex 6–8 F, Aspirex® 6–10 F), aspiration capacities of up 
to 1.5 mL/s can be achieved for the 8 F Rotarex system. The 
larger systems are especially used in the area of the pelvis and 
thigh where thrombotic occlusions mean larger vessel diam-
eters to deal with and greater volumes of thrombotic material 
to be removed. Depending on the size of the target vessel, the 
6 F system can be used to conduct a thrombectomy far into the 
lower leg. A standard 4 F system for distal lower leg procedures 
is in the planning stages, according to the manufacturer, and 
could provide therapy options up into the foot region.
After conducting a diagnostic angiography, a 6 F or 8 F 
diameter Rotarex system should be used, depending on the 
vessel diameter. Then, using roadmap or overlay technique, 
a 0.018 inch guide wire is inserted up to the target lesion 
and advanced distally beyond it. The Rotarex system is 
advanced over this guide wire up to a few centimeters above 
the thrombotic occlusion and then activated. The occlusion 
should be passed slowly. A slow passage is especially recom-
mended for subacute occlusions with material that is already 
partially organized in order to prevent peripheral embolisms 
(see Figure 2).
Small forward and backward movements should be made. 
Depending on the final morphology after reestablishing flow, 
an angioplasty with or without stent implantation must be 
considered, in keeping with the current recommendations. 
We conducted effective antithrombotic therapy with heparin 
during the procedure, with managed ACT (200–250 sec-
onds). Saturation with acetylsalicylic acid was also carried 
out. If a stent was implanted, clopidogrel saturation with 
600 mg was performed, with subsequent continuation for 
4 weeks.
Methods and results
From June 2008 to June 2010, a total of 22 patients (twelve 
male) with acute occlusions of a femoropopliteal bypass 
(twelve venous bypasses, ten polytetrafluoroethylene [PTFE] 
bypasses) were treated with the Rotarex system in our clinic 
(Tables 1 and 2, Figures 3–6). In this tracked study group, 
only P1 bypasses (proximal popliteal artery) were treated and 
evaluated. Clinically, ten patients exhibited stage I and twelve 
patients stage IIa acute ischemia of the extremities according 
to the recognized TASC classification. The presumed duration 
of the occlusions, according to the patients’ medical histories 
(onset of complaints to clinical presentation) was 10 ± 6 days. 
The average ankle-brachial index (ABI) value before the 
procedure was 0.42 ± 0.1 on the affected side. The age of the 
bypasses could not be determined for certain due to divergent 
statements; therefore, a decision was made not to indicate 
the average age of the bypasses. In ten patients, a high-grade to 
filiform bypass insertion stenosis was shown angiographically 
as a possible cause of the femoropopliteal bypass occlusion, 
which was treated in each case with a nitinol stent implanta-
tion (nine patients) or a conventional balloon angioplasty 
(one patient). None of the patients had an upstream bypass 
stenosis. In six patients, the presumed cause was determined 
to be a cardioembolic event in subsequent examinations. One 
patient had a large aneurysm of an approximately 18-year-old 
venous bypass upstream of the distal anastomosis. Here, the 
Table 1 Patient data
Patients (n) 22
Age (years) 70.2 ± 15.3
Men 12
Women 10
smokers 15
Ex-smokers 5
Dyslipoproteinemia 18
Diabetes mellitus 10
Hypertension 
Coronary artery disease (CAD)
16 
12
ABi value prior to procedure 0.41
stage i ischemia 10
stage iia ischemia 12
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aneurysm was eliminated with a Viabahn® endoprosthesis 
in a second procedure since the patient refused a revision 
operation (Figure 7). The thrombectomy was conducted 
in twelve patients using the 8 F Rotarex system, and in 
the remaining patients with the 6 F system. All procedures 
were conducted using crossover technique; for this reason, 
the 110 cm Rotarex shaft length was used in all cases. The 
crossover maneuver was possible in all cases. Prior to the 
procedure, the patients received a heparin bolus of 5000 IU 
heparin and 500 mg aspirin. In the cases in which a nitinol 
stent had to be implanted, saturation with clopidogrel 600 mg 
was performed while the patient was still in the angiography 
lab, and then clopidogrel 75 mg was recommended for these 
patients for 4 weeks. Overall, an average of 4 ± 2 throm-
bectomy passes were performed with the Rotarex system, 
beginning each time proximally in the occlusion with light 
forward and backward movements. The supplied 0.018 inch 
guide wires were used as the standard guide wire in almost 
all cases. In all cases, this guide wire was able be guided 
through the thrombotic occlusion. To verify a safe intravas-
cular position of the guide wire, a local injection of contrast 
agent was performed in all patients via an   over-the-wire 
catheter, which was inserted beforehand over the guide wire 
into the periphery. The average occlusion length was about 
30 cm. In five patients, due to the detection of a thrombus 
in popliteal artery segments II and III, a rotation thrombec-
tomy also had to be performed in these vessel segments, 
each time with a good early angiographic result. None of 
the patients experienced a vessel dissection or perforation. 
In four patients, local lysis still had to be performed after 
the Rotarex thrombectomy via an appropriate catheter since 
significant residual thrombi were still detected after several 
thrombectomy passes. Because of the persisting thrombus 
load, local lysis was performed in this patient with a tissue-
plasminogen activator (Actilyse®) for up to 24 hours (bolus 
5 mg, 1–3 mg/h) with a pulse-spray catheter. The average 
ABI value after the procedure was 0.85 ± 0.1. Six months 
after the index procedure follow-up studies were performed 
on 21 out of 22 patients. Follow up included ABI measure-
ment, clinical examination of the patient, and a Doppler and 
duplex study of the femoropopliteal bypass and the outflow 
vessels. The walking capacity was measured using a standard-
ized treadmill test in the patients who were able to perform 
this test. One patient refused follow-up examination.
Table 2 Vessel data
Length of occlusion in femoropopliteal bypass (cm) 28 ± 10 cm
Venous bypass 12
Artificial bypass graft (PTFE) 10
P1 segment femoropopliteal bypass 22
Age of bypass (months) 
Crural outflow vessels
2–120 months 
3 (10 patients) 
2 (8 patients) 
1 (4 patients)
Abbreviation: PTFE, polytetrafluoroethylene.
Figure 1 The Rotarex® system. Figure 3 Acute proximal occlusion of a femoro-popliteal bypass on right.
Figure 2 Contraindications for Rotarex use.
Contraindications
If it is impossible to penetrate the lesion with 
the guide wire 
Subintimal position 
Use in vessels with too small diameter
(<4 mm) 
If it is impossible to achieve sufficient 
anticoagulation 
Patient with coagulation system disorders 
•
•
•
•
•
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
285
Percutaneous mechanical thrombectomyVascular Health and Risk Management 2012:8
femoropopliteal bypasses, since only monocentric studies 
and individual case studies have been reported. A paper 
by Wissgott et al10 demonstrated, in a direct comparison 
between the Rotarex system and the EKOS Lysus® periph-
eral catheter system, a technical success rate of 100% for 
the Rotarex system in this indication, and also documented 
a significantly shortened procedural time with the Rotarex 
system. Patients with femoropopliteal bypasses that had been 
occluded for up to 14 days were included in the particular 
treatment   regimen. A majority of the patients were found to 
be in stage I or IIa of acute ischemia of the extremities. The 
8 F Rotarex catheter was used in most cases (twelve patients), 
while the other occluded bypasses were successfully reopened 
with the 6 F Rotarex catheter. The Zeller Working Group 
likewise reports a high rate of technical success following 
rotation   thrombectomy.7 By performing a stent-optimized 
angioplasty following the thrombectomy, a high percentage 
(78%) of very good early functional results were achieved 
(see Table 4). We can report similarly positive results with a 
PMT-based technical success rate of 100% in the collective 
we observed. Except for four patients, local lysis was not 
necessary due to significant residual thrombi still in situ. In 
cases of inadequate removal of the thrombus load, local lysis 
was performed following the PMT with tissue plasminogen 
activator (Actilyse®) using a pulse-spray   catheter. Due to the 
PMT conducted beforehand, the thrombus load was usually so 
greatly reduced that only very low-dose lysis was necessary 
(t-PA bolus 5 mg, 1–3 mg/h). Through this form of hybrid 
therapy, good long-term courses were able to be documented, 
Figure 4 Reperfusion after two rotation thrombectomy passes.
Figure 5 Detection of a high-grade insertion stenosis of the bypass as the presumed 
cause of the occlusion.
Clinically, none of the patients could be classified in 
a Rutherford stage greater than II. The average ABI value 
was 0.81 ± 0.1. Average walking capacity was 323 m. No 
re-interventions were necessary in any of the patients during 
this 6-month period (Table 3).
Efficacy analysis of the Rotarex system 
in the indication of acutely occluded 
femoropopliteal bypasses
To date, there has been no extensive, systematic scientific 
review of the Rotarex system’s use in acutely occluded 
Figure 6 Normal flow in the bypass following stent percutaneous transluminal 
angioplasty.
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even in larger native vessel areas (aorta, pelvic circulation).5 
In several cases, a high-grade, hemodynamically relevant 
insertion stenosis was able to documented as the cause of the 
femoropopliteal bypass occlusion, which was then treated in 
the same session. In the follow-up observation of our col-
lective, no renewed bypass occlusions or hemodynamically 
relevant restenoses occurred within a period of 6 months. After 
6 months, the ABI value was 0.81 ± 0.1. The data correspond 
to the empirical values of Wissgott et al,6,10 who followed their 
patient collective over 12 months and describe a primary pat-
ency rate of 66% and a secondary patency rate of 86%. Zeller 
et al assessed the course of their study collective significantly 
more critically because in these patients a restenosis rate of 
86% at 12 months was determined. We can only speculate 
about the cause of this. A possible reason is surely the fact that, 
in the collective of Zeller et al, only patients with an artificial 
bypass were examined.7,8 In the collective we describe and in 
that of Wissgott et al, the percentage of artificial bypass throm-
bectomies was significantly smaller. The cause of the elevated 
reintervention rate for PTFE bypasses lies in the “foreign body 
reaction” of the vessels, which has been scientifically proven 
and   recognized.11 Since the restenosis rate in the collective of 
Zeller et al suddenly jumped after 6 months, one of the causes 
may lie in a proliferative restenosis of the anastomosis area, 
making repeat interventions or operations necessary.
A great advantage of the PMT system compared with 
local lysis is the minimization of systemic bleeding compli-
cations, which were documented in particular in the large 
lysis studies.2,3
In our collective, there were no larger bleeding complica-
tions except for smaller inguinal hematomas. The patients 
we treated only had to stay in the intensive care unit for a 
few hours and were able to leave the hospital, on average, 
after 3.4 days. In some cases, in patients in whom a cardi-
oembolic event was suspected, embolism source diagnostics 
were later conducted.
Complications, in general, using the rotational throm-
bectomy device are described. In some patients part of the 
thrombus could be advanced further down in the treated 
  vessel, which makes a local lysis therapy necessary especially 
in the crural vessels. Puncture-associated complications 
increase with the 8 F Rotarex system, like groin hematoma, 
aneurysm, and bleeding complications. This is even more 
likely in patients who need additional local lysis therapy. In 
our opinion, the technical problems of the Rotarex system 
reported in earlier papers,7 particularly the danger of helix 
breakage in acute aortoiliac bifurcations, no longer exist in 
the current generation of the system. Especially through a 
further development of the enveloping shaft material with 
high   flexibility, the danger of helix breakage in crossover 
use appears to be significantly reduced in the most up-to-date 
Rotarex version. Because of this, acute aortoiliac angles no 
Figure 7 Degeneratively altered femoropopliteal venous bypass on right following acute reopening with rotation thrombectomy (Rotarex® 8 F). 
Notes: Large bypass aneurysm upstream of the distal anastomosis. Elimination of the aneurysm in two steps using a Viabahn® endoprosthesis.
Table 3 six-month follow-up data
Followed up patients 21/22
Rutherford stage i (15 patients) 
ii (6 patients)
Walking capacity 323 m
Ankle brachial index (ABi) 0.81 ± 0.1
Death 
Reinterventions
0/22 
0/21
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longer pose a significant problem in comparison with the ear-
lier Rotarex generation.5 The incidence of device-associated 
vessel perforations or dissections is low when care is taken 
with the intravascular course of the guide wire and it is 
monitored. In a collective of 40 patients from our clinic with 
thrombectomy, each in native vessels, uncomplicated dissec-
tion was shown in five of the patients. No perforation with a 
necessary (covered) stent implantation occurred. None of this 
type of complication occurred in the collective reported here. 
Experience has shown that there is a particularly greater risk 
in highly calcified vessels, the cause here appearing to be the 
aspiration of a hard calcified plaque that catches in the inlet of 
the helix. This can cause the rotating helix to produce a strong 
pull on the arterial wall, which can lead to perforation.
Rotation thrombectomy is included in the German DRG 
system. The procedure “rotation thrombectomy” is listed under 
DRG F 59 A for diagnosis I 74.3 (embolic occlusion).
Summary
The Rotarex system offered by Straub appears to be an 
effective alternative in the treatment of acute and subacute 
femoropopliteal bypass occlusions in comparison to estab-
lished therapies such as vascular surgery and local lysis. The 
system is available for use to an experienced intervention 
team within a few minutes and is simple to handle. Because of 
the offer of both 6 F and 8 F devices, the appropriate system 
for the corresponding thrombus load can be used. Whenever 
possible, we recommend using the 8 F Rotarex system in the 
indication of femoropopliteal bypass occlusion in order to 
reduce the thrombus load as much as possible and to avoid 
any additional lysis. Therefore, an effective interventional 
treatment possibility is available to the affected patient, 
which avoids open vascular surgery. Especially in patients 
who are not candidates for an open procedure due to their 
comorbidities, this technique seems to be a promising inter-
ventional alternative.
The data should be considered as a presentation of 
preliminary data and results with the Rotarex device for 
femoropopliteal bypass acute occlusion in a small group of 
patients from a single center. As no control group was cre-
ated, ie, a group of patients with occluded femoropopliteal 
bypasses treated with conventional (surgical) techniques, we 
were not able to compare both strategies directly. Our next 
step will be to plan a randomized, multicenter, prospective 
trial with direct comparison of interventional and surgical 
treatment to answer these questions.
Consequences for clinic  
and practice
Acute ischemia of the extremities represents a risk for the 
entire body in addition to the danger for the affected limb, 
since organs such as the kidneys, heart, and brain may also 
suffer due to the anaerobic metabolic situation caused by the 
hypoperfusion. Therefore, rapid diagnosis and an effective 
revascularization strategy are important measures for the 
patient. In these cases, percutaneous mechanical thrombec-
tomy is an effective and safe endovascular therapy option in 
addition to the established lysis therapy.
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